About Trillium Therapeutics (TSE:TRIL)
Trillium Therapeutics Inc., a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company's lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies and solid tumors therapy. Its product candidates also include TTI-622, an IgG4 SIRPaFc protein for combination therapy; bromodomain inhibitor; and epidermal growth factor receptor antagonist, which are in preclinical development stage, as well as undisclosed immuno-oncology targets that are in the discovery Phase. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was founded in 2004 and is headquartered in Mississauga, Canada.
Industry, Sector and Symbol
Trailing P/E Ratio-1.92307692307692
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on Equity-259.65%
Return on Assets-55.25%
Trillium Therapeutics (TSE:TRIL) Frequently Asked Questions
What is Trillium Therapeutics' stock symbol?
Trillium Therapeutics trades on the Toronto Stock Exchange (TSX) under the ticker symbol "TRIL."
Who are some of Trillium Therapeutics' key competitors?
Some companies that are related to Trillium Therapeutics include Cona Resources (CONA), Aimia (AIM), Storm Resources (SRX), Acasta Enterprises (AEF), Kelt Exploration LNG (RTK), Wesdome Gold Mines (WDO), Inovalis Real Estate Investment Trust (INO.UN), IBI Group (IBG), Cervus Equipment (CERV), BTB Real Estate Investment Trust (BTB.UN), TECSYS (TCS), Asanko Gold (AKG), NAPEC (NPC), Stuart Olson (SOX), High Arctic Energy Services (HWO), GDI Integrated Facility Services (GDI), NewCastle Gold (NCA) and Yellow Pages (Y).
Who are Trillium Therapeutics' key executives?
Trillium Therapeutics' management team includes the folowing people:
- Calvin R. Stiller M.D., Independent Chairman of the Board
- Niclas Stiernholm, President, Chief Executive Officer, Director
- James T. Parsons, Chief Financial Officer
- Malik Slassi, Senior Vice President - Discovery Research
- Robert Uger, Chief Scientific Officer
- Scott Duncan, Director of Intellectual Property
- Penka Petrova, Chief Development Officer
- Eric L Sievers, Chief Medical Officer
- Luke M. Beshar CPA, Independent Director (Age 59)
- Henry Friesen M.D., Independent Director (Age 79)
Has Trillium Therapeutics been receiving favorable news coverage?
News stories about TRIL stock have trended somewhat positive this week, Accern Sentiment reports. Accern rates the sentiment of news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Trillium Therapeutics earned a coverage optimism score of 0.24 on Accern's scale. They also gave news coverage about the company an impact score of 47.06 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near future.
How do I buy shares of Trillium Therapeutics?
Shares of TRIL and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is Trillium Therapeutics' stock price today?
One share of TRIL stock can currently be purchased for approximately C$9.81.
How big of a company is Trillium Therapeutics?
Trillium Therapeutics has a market capitalization of C$124.24 million.
How can I contact Trillium Therapeutics?
Trillium Therapeutics' mailing address is 2488 Dunwin Dr, MISSISSAUGA, ON L5L 1J9, Canada. The company can be reached via phone at +1-416-5950627.
MarketBeat Community Rating for Trillium Therapeutics (TRIL)MarketBeat's community ratings are surveys of what our community members think about Trillium Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Trillium Therapeutics (TSE:TRIL) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
Earnings History for Trillium Therapeutics (TSE:TRIL)
No earnings announcements for this company have been tracked by MarketBeat.com
Trillium Therapeutics (TSE:TRIL) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Trillium Therapeutics (TSE:TRIL)
No dividend announcements for this company have been tracked by MarketBeat.com
Trillium Therapeutics (TSE TRIL) Insider Trading and Institutional Ownership History
Trillium Therapeutics (TSE TRIL) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|7/7/2017||Gordon Edward Zelko||Director||Buy||93,000||C$0.11||C$10,230.00|
|6/30/2017||Michael Bruno John Fr England||Director||Buy||54,000||C$0.11||C$5,940.00|
|6/15/2017||John Parker Masters||Director||Buy||50,000||C$0.12||C$6,000.00|
|6/6/2017||Michael Bruno John Fr England||Director||Buy||19,000||C$0.11||C$2,090.00|
|5/2/2017||Michael Bruno John Fr England||Director||Buy||100,000||C$0.15||C$15,000.00|
|4/20/2017||Michael Bruno John Fr England||Director||Buy||11,500||C$0.12||C$1,380.00|
|4/19/2017||Michael Bruno John Fr England||Director||Buy||50,000||C$0.12||C$6,000.00|
|4/13/2017||Donald Laughlin Mckinnon||Director||Buy||20,000||C$0.13||C$2,600.00|
|4/10/2017||Michael Bruno John Fr England||Director||Buy||12,000||C$0.10||C$1,200.00|
|3/27/2017||Michael Bruno John Fr England||Director||Buy||5,000||C$0.19||C$950.00|
|3/22/2017||Gordon Edward Zelko||Director||Buy||20,000||C$0.10||C$2,000.00|
|2/17/2017||Michael Bruno John Fr England||Director||Buy||50,000||C$0.12||C$6,000.00|
|2/7/2017||Gordon Edward Zelko||Director||Buy||50,000||C$0.11||C$5,500.00|
|1/31/2017||Michael Bruno John Fr England||Director||Buy||20,000||C$0.11||C$2,200.00|
Trillium Therapeutics (TSE TRIL) News Headlines
Trillium Therapeutics (TSE:TRIL) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
Trillium Therapeutics (TSE TRIL) Stock Chart for Friday, March, 23, 2018